Key Component of Immune System- ITERFERO Key Component of Immune System - ITERFERO
ITERFERO 1.? 2.? 3.? 4.? 5.? (Dr.Yasuhiko Kojima) 1950 50 1954 (Dr.Yasuhiko Kojima) 1957 Isaacs Lindenman 2 1960 Ion Gresser 1975 1980 1980 1980 (Dr.Yasuhiko Kojima) 200 6.? 7.? a.c 35 C1 b. 113 19982000 1810 1 2 8 1 2 1 2
c. 326 2 3 6 d. c. e. 5220~350.8 3 8.? 8.? 2004 SARS SARSAlbert Osterhaus SARS SARS 1000 SARS(150eq/ml)SARS SARS SARSSARS 9.? 9.? a. b. c. d. a. b.?? 4 c. d.40 14.? 14.? a. b. c. d. 13.? 13.? 3001000 2 3 6 10 15 15.? 15.? 12.? 12.? 11.? a. b. d. g. e. f. c.
16.? a.bc b. c. 17.? a. b. c. 18.? a. b. c. d. e. f. g. a. (Cucurbita moschata) b. (Plantago asiatica) (stimulate non-specific immunity) c. (Carthamus tinctorius) (Lonicera japonica) 1.C C C (Kanazawa University Hospital in Ishikawa, Japan) 35 C 1 C 5 6
2. 參考文獻 19982000 113 182 10 1 2 8 2 3. (Osaka Medical College, Osaka, Japan) 32 2 (Greene's Climacteric Scale) (Visual Analog Scale) (plasma TG) (LDL-cholesterol) 4. 32 (FSH) (GM-CSF ) 1. Pegylated interferon-a protects type 1 pneumocytes against SARS coronavirus infection in macaques. ature Medicine, published online, doi:10.1038/nm1001 (2004). 2. Kaji, S. Yoshida,. agata, T. Yamashita, E. Mizukoshi, M. Honda, Y. Kojima and S. Kaneko: An Open-Label Study of Administration of EH0202, a Health Food Additive, to Patients with Chronic Hepatitis C. Journal of Gastroenterology. 2004; Sep;39(9):873-8. 3. Studies with pollenosis formula including an open-labeled trial with allergy patients at Yamanashi Medical University, Japan, June 2000 (Unpublished). 4. T. Ushiroyama, S. Yoshida, and K. Tadaki: Clinical Efficacy of EH0202, a Kampo Formula on the Health of Middle-Aged Women. American Journal of Chinese Medicine. 2004;32:(5):755-70. 5. T. Ushiroyama, S. Yoshida, K. Tadaki, A. Ikeda and M. Ueki: A pilot study of a Kampo formula, EH0202, with intriguing results for Menopausal symptoms. Journal of Alternative and Complementary Medicine. 2004 Apr;10(2):397-9. 6. M. Kubo, Y. Hashimoto and S. Yoshida: The effect of health food containing EH0202 on physical and mental symptoms accompanying menstruation in women with premenstrual syndrome (PMS). Clinical Pharmacology and Therapy. 2004;14(2):129-142. 7. Josiane Sanceau, John Hiscott, Olivier Delattre and Juana Wietzerbin. 2000. IF-? induces serine phosphorylation of Stat-1 in Eeing's sarcoma cells and mediates apoptosis via induction of IRF-1 and activitation of caspase-7. Oncogene. 19:3372-3383. 8. Husam M. Younes, Brian G. Amsden:Interferon-? therapy:evaluation of routes of administration and delivery system. J Pharma Sciences:91(1):2-17, 2002. 9. Farrar MA, Scheriber RD:The molecular biology of interferon-? and its receptor. Ann Rev Immunol 11:571-611, 1993 10. Samuel, C. E. 1991. Antiviral actions of interferon. Interferon-regulated cellular proteins and their surprisingly selective antiviral activities. Virology 183:1-11. 11. Throckmorton DC, Brogden AP, Min B, Rasmussen H, Kashgarian M:PDGF and TGF-? mediate collagen production by mesangial cells exposed to advanced glycosylation end products. Kidney Int 48 :111-117, 1995. 12. Saacs A, Lindenmann J. Virus interference. The interferon. Proc R Soc B. 1957; 147(1): 258. 13. Studies with pollenosis formula including an open-labeled trial with allergy patients at Yamanashi Medical University, Japan, June 2000 (Unpublished). 5. 42 20~35 0.8 7 8